Creative Medical Technology Holdings Inc./$CELZ
1D1W1MYTD1Y5YMAX
Capital at risk
About Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
- Ticker
- $CELZ
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4
- Headquarters
- Phoenix, United States
CELZ Metrics
BasicAdvanced
$5.8M
-
-$1.95
1.94
-
Price and volume
Market cap
$5.8M
Beta
1.94
52-week high
$6.25
52-week low
$0.62
Average daily volume
12M
Financial strength
Current ratio
12.91
Quick ratio
12.653
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-6.126
Gross margin (TTM)
66.87%
Net profit margin (TTM)
-201,355.37%
Operating margin (TTM)
-208,003.33%
Management effectiveness
Return on assets (TTM)
-47.32%
Return on equity (TTM)
-77.88%
Valuation
Price to revenue (TTM)
904.639
Price to book
0.66
Price to tangible book (TTM)
0.69
Price to free cash flow (TTM)
-0.46
Free cash flow yield (TTM)
-217.49%
Free cash flow per share (TTM)
-1.908
Growth
Revenue change (TTM)
-50.00%
Earnings per share change (TTM)
-35.12%
3-year revenue growth (CAGR)
-65.59%
3-year earnings per share growth (CAGR)
-33.46%
Upcoming events
No upcoming events
CELZ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.